{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-046861","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2026-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.034349+00:00","generated_at":"2026-05-15T04:55:27.124365+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Barinthus appoints Douglas Swirsky as CFO, effective May 1, 2026","bullets":["Swirsky appointed Chief Financial Officer and principal accounting officer, effective May 1, 2026.","Previously served as CFO of MaxCyte (2023-2026) and AavantiBio; CEO of Rexahn Pharmaceuticals.","Compensation: $20,000 per month via master services agreement with Grand Strand BioAdvisors LLC.","Company will provide D&O insurance and indemnification on terms no less favorable than other officers."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-046861","json":"https://secwatch.observer/filing/0001104659-26-046861.json","markdown":"https://secwatch.observer/filing/0001104659-26-046861.md","text":"https://secwatch.observer/filing/0001104659-26-046861.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926046861/0001104659-26-046861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926046861/tm2612491d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:55:27.124365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}